Dev elopmental disabilities occur in approximately 5-10% of the childhood population. 1 Global dev elopmental delay is described as occurring when there is signif icant delay in two or more dev elopmental domains (gross motor, f ine motor, cognition, speech/language, and personal/social). The term global dev elopmental delay is def ined as perf ormance at least two standard dev iations below the mean of age appropriate, standardised norm ref erenced dev elopmental testing. 1 This term is used f or y ounger children (ty pically less than 5 y ears), whereas the term mental retardation is used f or older children where IQ testing is more reliable. Global delay prev alence is estimated to be 1-3% of children aged less than 5 y ears. 1
Identif ication of dev elopmental delay occurs in countries with well dev eloped sy stems of health care through surv eillance programmes but may be recognised by parents, the f amily doctor, or other health practitioners. Once recognised, dev elopmentally delay ed children are f requently ref erred to a paediatrician; more commonly community based but in some areas hospital clinics. This assessment will conf irm the existence of delay , characterise the domains af f ected, and attempt to establish the aetiology . Af ter history and examination are complete, conf irmation of aetiology of the dev elopmental delay may be possible in approximately one f if th of children. 2 Thereaf ter laboratory inv estigations and other inv estigativ e approaches are considered, such as magnetic resonance imaging of the brain. The commoner causes of dev elopmental delay are chromosomal abnormalities and structural brain abnormalities. 2 One of the challenging questions f or paediatricians inv estigating children with dev elopmental delay is how intensiv ely should one inv estigate f or inborn errors of metabolism and which metabolic inv estigations are indicated.
Reports on the prev alence of inborn errors of metabolism (IEMs) as the underly ing cause of delay show some v ariation but generally indicate that IEMs are f ound to be the cause in only a small percentage of these cases 3 (that is, 1-5%). In f act the American College of Medical Genetics in 1997 recommended omitting metabolic screening in unselected cases of dev elopmental delay . 3 The report f rom the American Academy of Neurology and the Practice Committee of the Child Neurology Society of f ers guidelines based on a rev iew of published literature. "Screening" metabolic inv estigations are recommended especially where newborn screening is absent or minimal, and directed metabolic tests are adv ocated thereaf ter based on clinical f indings. 1 The incidence and range of IEM as a cause of dev elopmental delay is likely to v ary between dif f erent populations; of note the more recent reported series are f rom the USA. 1,3 There is a paucity of data on the detection of metabolic disorders when inv estigating dev elopmental delay in the United Kingdom. A report f rom 1998 identif ied the wide v ariation both in the number and ty pe of inv estigations chosen by a group of UK community paediatricians when inv estigating dev elopmental delay . 4 Unpublished data of a retrospectiv e analy sis (1995-2001) of requests f or IEM inv estigations to the Clinical Biochemistry Department at Birmingham Children's Hospital diagnosed 40 cases of IEM ov er a six y ear period. The commonest causes were disorders of organic and amino acid metabolism and the mucopoly saccharidoses. This was not a sy stematic study and theref ore we do not know how many total cases of dev elopmental delay were diagnosed in that period; no conclusions about prev alence of IEM in this population can theref ore be drawn. Howev er, the ty pes and range of disorders f ound are probably representativ e of other larger UK conurbations with a similar ethnic mix. Another interesting f eature of these diagnoses was the f inding of unrelated disorders-that is, where the biochemical def ect was not a cause of the dev elopmental delay ; f or example, cy stinuria and other biochemical abnormalities with no associated clinical ef f ects, e.g. prolinaemia, sarcosinaemia.
IEM are rare causes of isolated dev elopmental delay . More usually , an IEM occurs in association with other clinical clues. Howev er, despite their relativ ely low incidence, IEMs remain extremely important causes to determine since specif ic therapies may be av ailable f or the condition, acute metabolic decompensation may be av oidable, and accurate prognosis and genetic counselling can be of f ered. Unlike other parts of the world, in the UK, univ ersal newborn screening is currently restricted to pheny lketonuria and congenital hy pothy roidism (CHT); other IEMs, f or example, maple sy rup urine disease, urea cy cle def ects, and organic acid disorders will not theref ore be diagnosed by this route. In some countries newborn screening by tandem mass spectrometry will detect organic acid disorders, and some amino acid and urea cy cle disorders. 3,6 It is particularly important, theref ore, to inv estigate inf ants/children with dev elopmental delay where extended newborn screening f or metabolic disorders is not prov ided. Although the newborn screening programme in the UK should detect primary CHT, patients with secondary or acquired late onset f orms will not be diagnosed.
This article describes an inv estigativ e approach to the child with dev elopmental delay f ocusing on the appropriate testing f or IEMs. It is not an ev idence based approach due to the lack of av ailable UK data; it is a practical guide to inv estigating children with dev elopmental delay based on personal practice f rom two major paediatric centres within the UK.
CLUES FROM HISTORY AND EXAMINATION
In the history there may be sev eral important f eatures to suggest an IEM (table 1). The prev ious f amily history should be explored f or ev idence of consanguinity and unexplained neonatal or inf antile deaths; this should include a three generation pedigree. The pregnancy and birth details should be noted. Children with IEMs are usually born of normal birth weight and in good condition. Exceptions to this are those disorders which hav e intra-uterine or immediate ef f ects f ollowing birth, such as non-ketotic hy pergly cinaemia and disorders of py ruv ate metabolism. A history of maternal acute f atty liv er of pregnancy (AFLP) or haemoly sis elev ated liv er enzy mes and low platelets (HELLP) is associated with sev eral f atty acid oxidation disorders.
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The past medical history of the dev elopmentally delay ed child should be questioned in detail. Usef ul clues to an underly ing IEM are a history of hy pogly caemia, an episode of unexplained encephalopathy , or an extreme reaction requiring hospitalisation to an otherwise supposed mild illness such as gastroenteritis. Some children may hav e unusual f ood behav iours such as protein av ersion seen most commonly in the urea cy cle disorders. A history of self -injurious behav iour can be seen in Lesch-Ny han sy ndrome and hy perammonaemia; other psy chiatric abnormalities can be associated with disorders of cobalamin and later onset ly sosomal storage disorders. The nature of the dev elopmental delay should be recorded. Any suggestion of regression of skills makes an IEM much more likely and merits intensiv e inv estigation. The pattern of delay can sometimes be of help: hy potonia causing gross motor delay is seen in the organic acidurias, f atty acid oxidation disorders, (FAOs) and urea cy cle def ects; and speech delay is of ten the f irst sign of Sanf ilippo sy ndrome (mucopoly saccharidosis ty pe III). Generalised delay with associated sensori-motor hearing loss suggests a mitochondrial disorder. Seizures may occur in association with dev elopmental delay . A sev ere seizure disorder in the newborn period occurs in non-ketotic hy pergly cinaemia, peroxisomal disorders and in sulphite oxidase/moly bdenum cof actor def iciency . Bey ond inf ancy , epilepsy is quite common in mildly delay ed children and would not specif ically indicate an IEM. A sev ere seizure disorder and delay is seen in many of the ly sosomal storage disorders, but in these cases there is usually neurological regression giv ing stronger indication of IEM. The newly described group of creatine def iciency disorders can cause seizures and dev elopmental delay , although more usually there are extrapy ramidal mov ements and hy potonia.
Examination f indings can be v ery helpf ul (table 2) . Dy smorphic f eatures may lead to a sy ndromic diagnosis or suggest specif ic IEMs such as Smith-LemliOpitz sy ndrome. The presence of hepatosplenomegaly accompany ing dev elopmental delay is highly suggestiv e of a ly sosomal storage disorder (LSD). Other f eatures that may be present in LSDs are corneal clouding, f acial coarsening, and dy sostosis multiplex on skeletal surv ey . Cardiac muscle abnormalities such as hy pertrophic or dilated cardiomy opathy are seen in FAOs where the dev elopmental delay is usually in the gross motor domain due to hy potonia. A characteristic odour is associated with certain organic acidurias such as maple sy rup urine disease (sweet) and isov aleric aciduria ("sweaty f eet") but is rarely a leading sign. Specif ic neurological signs such as dy stonia make one suspect an IEM. In particular, dy stonia is f requently a manif estation of mitochondrial disease and organic acidurias af ter a metabolic crisis in which basal ganglia are damaged. Macrocephaly is seen in Canav an's disease, L-2-hy droxy glutaric aciduria, glutaric aciduria ty pe I, and Tay -Sach's disease, while microcephaly is characteristic of sulphite oxidase def iciency but may be seen as a result of prev ious metabolic encephalopathy due, f or example, to hy perammonaemia. The of f spring of poorly controlled or unrecognised pheny lketonuria (PKU) hav e microcephaly . This diagnosis is especially worth considering where the mother has emigrated to the UK f rom a country where univ ersal newborn screening f or PKU is not undertaken.
In this window In a new window Table 2 Examination f indings Despite all these possible clues, the most common situation challenging paediatricians is of the child with global dev elopmental delay and no accompany ing clues on history or examination. Inv estigation of these children giv es a low y ield f or IEMs; prev ious data suggest that the y ield af ter metabolic inv estigation in this group is 1-5%. 1 It is proposed that a reasonable and saf e approach theref ore is to limit inv estigation to the battery of baseline tests in table 3. Interpretation of these baseline tests requires consideration of their reliability and in particular f actors which may cause spurious or misleading results. Some of these f actors are discussed below.
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Baseline inv estigations; global delay with no specif ic associated f indings Blood lactate can be a usef ul screen f or disorders of energy metabolism. These include disorders of gluconeogenesis, disorders of py ruv ate metabolism, and respiratory chain mitochondrial disorders. If there is associated hy pogly caemia then gluconeogenic disorders are more likely . Care is needed, howev er, in interpreting a high blood lactate. Excessiv e screaming, tourniquet pressure or haemoly sis may cause an erroneously elev ated lactate lev el, making mildly elev ated lactate lev els (up to 3 mmol/l) dif f icult to interpret. Increased lactate accompanied by elev ation of plasma alanine and proline suggests a chronic lactic acidaemia, thereby aiding intepretation. CSF lactate is a more reliable indicator of elev ated lactate and can ev en be raised when plasma lactate is normal if the clinical presentation is largely neurological. Similar care is needed in interpreting blood ammonia lev els as it may too be artif icially elev ated by the same circumstances as lactate, with the added problem of contamination. Elev ated ammonia suggests inadequate f unction of the urea cy cle. This may be due to a primary urea cy cle def ect or secondary to liv er disease, drugs such as sodium v alproate, or another inborn error. Urine organic acids should detect nearly all organic acid def ects and some f atty acid oxidation def ects. Howev er it is important to be aware that some disorders may be dif f icult to detect with biochemical tests when the child is well as abnormalities in these circumstances may be minimal. Repeat testing during the illness is theref ore important. Raised creatine kinase is a non-specif ic f inding in f atty acid oxidation def ects or other disorders af f ecting muscle. Urate measurement has been included as a low concentration may indicate a def ect of purine metabolism or moly bdenum cof actor def iciency and a high concentration is seen in sev eral IEMs such as Lesch-Ny han sy ndrome and gly cogen storage disorders. Urinary gly cosaminogly cans hav e been included in the f irst line screen since mucopoly saccharidosis ty pe III (Sanf illipo disease) can present solely as dev elopmental delay . 5 Since the coarse f acial dy smorphism ty pically associated with MPS disorders is generally absent in this condition, clinicians may not consider an MPS disorder as a cause of pure dev elopmental delay .
These tests should diagnose or prov ide clues to many IEM including organic acid, amino acid, urea cy cle def ects, f at oxidation disorders, and mucopoly saccharidoses. Serial rev iew in children with dev elopmental delay is important. Time may rev eal a new sy mptom such as the repetitiv e hand mov ements of Rett sy ndrome, or a protein av ersion may become clearer as the child reaches an age where they would eat a more v aried diet.
Organomegaly becomes more obv ious as the disorder progresses and slowly ev olv ing regression is only obv ious as time elapses. A suggested time f rame f or rev iew of patients with dev elopmental delay with no aetiology is two assessments in the f irst y ear of lif e, annually until school age, and once more at puberty . In the absence of any associated specif ic f eatures, we do not recommend any additional metabolic inv estigations.
Specific investigations for IEM
In situations where dev elopmental delay is associated with a specif ic f inding-that is, hy potonia, regression, ey e abnormalities, hepatosplenomegaly , or dy smorphism it is v aluable to "tailor" inv estigations to those IEM which can present with these f actors. Table 4 groups disorders with associated tests, under these headings. Bef ore embarking on these inv estigations it may be appropriate to discuss the case with a specialist metabolic paediatrician. Af ter such discussion it is likely that specialised inv estigations are initiated in parallel with (or ev en by -passing) the baseline tests.
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The phy sician should consult the local specialist laboratory f or specimen requirements as details may v ary between laboratories. A metabolic assay directory is av ailable f or tests prov ided in the UK by the National Metabolic Biochemistry Network (www.metbio.net).
We suggest that f ollowing these guidelines makes "missing" an IEM extremely unlikely and f orms a rational basis f or the approach to inv estigating the child with dev elopmental delay f or the presence of IEM. The suggested staged approach minimises costs and limits the use of the most expensiv e tests to selected cases.
SUMMARY
While IEMs are not a common cause of dev elopmental delay , their inv estigation remains v ery important f or sev eral reasons: appropriate genetic counselling can be giv en; specif ic therapies may be av ailable; and clinicians can be aware of any associated risk of acute metabolic decompensation. When no diagnosis is made on f irst ref erral, there is v alue in rev iew at inf requent interv als as new f eatures may become apparent or new IEMs described. While it is almost impossible to assert that one has completely excluded an IEM, the inv estigativ e plan outlined abov e prov ides a sensible f ramework f or testing and would detect the v ast majority of IEMs that are associated with dev elopmental delay .
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